(Q24792449)

2

0 references

Kenji Nakata

3

0 references

Manabu Takaki

4

0 references

Akira Nomura

5

0 references

Takeshi Katsu

6

0 references

Yuji Tanaka

7

0 references

Takaki Imamura

8

0 references

Ayumu Sakai

9

0 references

Shigetoshi Kuroda

full work available at URL

10

0 references

language of work or name

English

0 references

publication date

21 October 2003

0 references

https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-3-13

file format

Portable Document Format

online access status

open access

1 reference

PubMed ID

14567761

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14567761

https://europepmc.org/articles/PMC270036

23 March 2024

1 reference

PubMed ID

14567761

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14567761

https://europepmc.org/articles/PMC270036?pdf=render

23 March 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

PubMed ID

14567761

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14567761

http://link.springer.com/content/pdf/10.1186/1471-244X-3-13.pdf

23 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1186/1471-244X-3-13

http://link.springer.com/article/10.1186/1471-244X-3-13/fulltext.html

23 March 2024

1 reference

https://api.crossref.org/works/10.1186/1471-244X-3-13

http://link.springer.com/content/pdf/10.1186/1471-244X-3-13

23 March 2024

1 reference

https://api.crossref.org/works/10.1186/1471-244X-3-13

23 March 2024

0 references

3

0 references

page(s)

13

0 references

issue

1

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1471-244x-3-13

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-244x-3-13

cites work

The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

Polymorphisms of the sigma(1) receptor gene in schizophrenia: An association study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

Naloxone-inaccessible sigma receptor in rat central nervous system

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

Sigma receptors: biology and function

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

sigma Receptor antagonists block the development of sensitization to cocaine.

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

Effect of NE-100, a novel sigma receptor ligand, on phencyclidine- induced delayed cognitive dysfunction in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

[3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270036

Sigma (σ) antagonist BMY 14802 prevents methamphetamine-induced sensitization

28 November 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

Selective loss of cerebral cortical Sigma, but not PCP binding sites in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

A proposal for the classification of sigma binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-3-13

21 January 2018

Pharmacological Reviews

2

42

355

JM Walker

1990

1 reference

https://api.crossref.org/works/10.1186/1471-244X-3-13

23 March 2024

Identifiers